Acute Hepatitis B in a Patient with Antibody to Hepatitis B Surface Antigen who was Receiving Chemotherapy for Acute Myelogenous Leukemia with Cytarabine and Daunorubicin

Abstract

Hepatitis B virus asymptomatic carriers should receive treatment in certain conditions, such as prior to chemotherapy and organ transplantation. In these groups interferon alpha has limited efficacy or is even contraindicated. In contrast, lamivudine is highly effective in both preventing of and treat- ment of HBV reactivation in these immunosuppressed patients. Prevention of reactivation has better results than treating reactivation.